Quantitative assessment of the impact of cryopreservation on human bone marrow-derived mesenchymal stem cells: up to 24 h post-thaw and beyond

  • Stem Cell Res Ther. 2020 Dec 14;11(1):540. doi: 10.1186/s13287-020-02054-2.
Soukaina Bahsoun  1 ,  Karen Coopman  2 ,  Elizabeth C Akam  3
Affiliations
  • 1. School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, Leicestershire, LE11 3TU, UK. [email protected].
  • 2. Centre for Biological Engineering, Loughborough University, Loughborough, Leicestershire, LE11 3TU, UK.
  • 3. School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, Leicestershire, LE11 3TU, UK.
Abstract

Background: The effects of cryopreservation on human bone marrow-derived mesenchymal stem cells (hBM-MSCs) are still ill-defined. In this study, a quantitative approach was adopted to measure several post-thaw cell attributes in order to provide an accurate reflection of the freezing and thawing impact.

Methods: Fresh and cryopreserved passage-matched cells from three different donors were discretely analysed and compared for their viability, Apoptosis level, phenotypic marker expression, metabolic activity, adhesion potential, proliferation rate, colony-forming unit ability (CFUF) and differentiation potentials.

Results: The results of this study show that cryopreservation reduces cell viability, increases Apoptosis level and impairs hBM-MSC metabolic activity and adhesion potential in the first 4 h after thawing. At 24 h post-thaw, cell viability recovered, and Apoptosis level dropped but metabolic activity and adhesion potential remained lower than fresh cells. This suggests that a 24-h period is not enough for a full recovery. Beyond 24 h post-thaw, the observed effects are variable for the three cell lines. While no difference is observed in the pre- and post-cryopreservation proliferation rate, cryopreservation reduced the CFUF ability of two of the cell lines and variably affected the adipogenic and Osteogenic Differentiation potentials of the three cell lines.

Conclusion: The data collected in this study clearly show that fresh and cryopreserved hBM-MSCs are different, and these differences will inevitably introduce variabilities to the product and process development and subsequently imply financial losses. In order to avoid product divergence pre- and post-cryopreservation, effective strategies to mitigate freezing effects must be developed and implemented.

Keywords
Cell therapy; Cryopreservation; Freezing; Human bone marrow-derived mesenchymal stem cells; Quantitative; Thawing.